NCT02698423

Brief Summary

The purpose of this study is to determine whether human-papillomavirus (HPV) self-sampling can be used as a primary screening test for unscreened women.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
667

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2011

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 23, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 3, 2016

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

July 2, 2017

Completed
Last Updated

June 6, 2018

Status Verified

May 1, 2018

Enrollment Period

4.3 years

First QC Date

February 23, 2016

Results QC Date

May 2, 2017

Last Update Submit

May 10, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Who Performed HPV Self-testing Compared to the Number of Participants Who Responded to the Invitation to Come to the Hospital for Pap Testing

    Compare the participation rate to cervical cancer screening for home-based human papillomavirus testing based on self-sampling versus clinic-based, physician-performed Pap testing.

    1 year

Secondary Outcomes (1)

  • Proportion of Women With a Positive HPV Self-test Who Underwent All the Recommended Follow-up Clinical Investigations.

    1 year

Study Arms (2)

Cobas HPV DNA test

EXPERIMENTAL

Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.

Device: Cobas HPV DNA Test

Papanicolau test

ACTIVE COMPARATOR

Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.

Other: Papanicolau test

Interventions

Women will receive a home-sent sample for HPV self-testing

Cobas HPV DNA test

Women will be invited to come in for a physician-performed Pap test

Papanicolau test

Eligibility Criteria

Age25 Years - 69 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • No previous cervical cancer screening test in the last three years

You may not qualify if:

  • pregnancy
  • previous hysterectomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Results Point of Contact

Title
Dr Manuela Viviano
Organization
Geneva University Hospitals

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 23, 2016

First Posted

March 3, 2016

Study Start

September 1, 2011

Primary Completion

January 1, 2016

Study Completion

January 1, 2016

Last Updated

June 6, 2018

Results First Posted

July 2, 2017

Record last verified: 2018-05

Data Sharing

IPD Sharing
Will share

Data will be used for scientific publications.